Search This Blog

Friday, April 28, 2023

Merck, AstraZeneca Lynparza wins limited label expansion endorsement

 

By an 11-1 tally, a panel of FDA advisors voted to expand the prostate cancer indication for Merck (MRK) and AstraZeneca's (AZN)

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)